Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

CJC-1295 (without DAC) and HGH Fragment 176-191 Interaction: Monitor | Peptide Database

Can you take CJC-1295 (without DAC) with HGH Fragment 176-191? Monitor interaction (47% confidence). See pharmacological analysis, organ load, safety flags, and dosing guidance.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

HGH Fragment 176-191

Growth Hormone Fragment | Fat Loss Peptide

Mimics the lipolytic region of human growth hormone by stimulating fat breakdown through beta-3 adrenergic receptor pathways. Unlike full HGH, it does not bind the growth hormone receptor, so it does not increase IGF-1 levels or interfere with glucose metabolism.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with HGH Fragment 176-191?

Yes, but with caution. Both CJC-1295 (without DAC) and HGH Fragment 176-191 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is CJC-1295 (without DAC) and HGH Fragment 176-191 safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and HGH Fragment 176-191?

Both CJC-1295 (without DAC) and HGH Fragment 176-191 affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and HGH Fragment 176-191?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and HGH Fragment 176-191 has a half-life of 15-20 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected topics

Follow this recovery question